Area of research
Molecular Biology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Advanced Breast Cancer Therapies, PI3K/AKT/mTOR signaling in cancer, PARP inhibition in cancer therapy, and Protein Degradation and Inhibitors.
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Abstract GS3-04: GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers
Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in <i>Akt1</i> E17K mutation positive advanced solid tumors